Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 6 of 79. Open to participants first (2,630), then studies with results posted, then the rest; newest registration first within each.

• Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial CancerNot yet recruitingNCT07369986Phase 2
• Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2
• Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRCRecruitingNCT07365592Phase 1/2
• HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICCRecruitingNCT07364305Phase 2
• Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal CancerNot yet recruitingNCT07363408Phase 1
• A Phase II Study of Utidelone With Toripalimab in Advanced Cervical CancerNot yet recruitingNCT07363330Phase 2
• A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.RecruitingNCT07362459Phase 3
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)RecruitingNCT07361510Phase 3
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingNCT07361497Phase 3
• Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsRecruitingNCT07360743Phase 2
• Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver MetastasesNot yet recruitingNCT07359456Phase 2
• Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
• A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruitingNCT07357220Phase 1/2
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2
• FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
• Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar CancerRecruitingNCT07353723Phase 2
• Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Phase 2
• KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic CancerRecruitingNCT07353645Phase 1/2
• Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCEnrolling by invitationNCT07353294Phase 1
• Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable HepatocellularNot yet recruitingNCT07352007Phase 2
• A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
• Application of mRNA Immunotherapy Technology in EB Virus Related DiseasesNot yet recruitingNCT07349836Early Phase 1
• Neoadjuvant Pembrolizumab in Patients With Stage IIb/c MelanomaRecruitingNCT07349303Phase 2
• Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07349225Phase 2
• A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNot yet recruitingNCT07348861Phase 2
• Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT GlioblastomaNot yet recruitingNCT07347210Phase 2
• Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue CancerNot yet recruitingNCT07346807Phase 2
• A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and NeckNot yet recruitingNCT07346196Phase 2
• Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive SurgeryRecruitingNCT07343596Not applicable
• Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
• Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma PeritoneiRecruitingNCT07341360Early Phase 1
• Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruitingNCT07339839Phase 1/2
• Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2
• The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingNCT07338981Phase 3
• Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingNCT07337447Phase 2
• A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)Not yet recruitingNCT07336953Phase 3
• Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaRecruitingNCT07336147Phase 2
• CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07335497Phase 1/2
• A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCCRecruitingNCT07334483Phase 2
• A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingNCT07332533Phase 2/3
• Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2
• A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]RecruitingNCT07331155Phase 2
• TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant ChemoimmunotherapyRecruitingNCT07330037Phase 2
• QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Phase 2
• A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07327229Phase 1/2
• LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Phase 2
• SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerRecruitingNCT07322341Phase 2
• Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
• Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerRecruitingNCT07320586Phase 2
• Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)RecruitingNCT07320105Phase 4
• Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular ClassificationRecruitingNCT07319429Phase 2/3
• A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07318883Phase 2/3
• Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast CancerNot yet recruitingNCT07317778Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Phase 1
• A Phase 1 Study of JMT108 in Participants With Advanced Solid TumorsRecruitingNCT07317505Phase 1
• Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRecruitingNCT07315854Phase 2
• A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
• QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNot yet recruitingNCT07315035Phase 2
• 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial CancerRecruitingNCT07314723Phase 2
• FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Phase 2
• LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm StudyRecruitingNCT07312422Phase 1/2
• Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLCRecruitingNCT07309952Phase 2
• Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line TherapyRecruitingNCT07309185Phase 2
• A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingNCT07304258Phase 2
• A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)RecruitingNCT07302347Phase 1/2
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaRecruitingNCT07301268Phase 2
• T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to ImmunotherapyNot yet recruitingNCT07300891Phase 2
• A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaRecruitingNCT07297212Phase 2
• Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBCRecruitingNCT07296705Phase 2
• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingNCT07293351Phase 1/2
• PULSAR Combined With Immunotherapy and ChemotherapyRecruitingNCT07291947Phase 1/2
• A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingNCT07291076Phase 1/2
• Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2
• Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerRecruitingNCT07290621Phase 2
• Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)RecruitingNCT07289997Phase 2
• Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingNCT07288814Phase 1/2
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2
• Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 TrialNot yet recruitingNCT07286942Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II TrialRecruitingNCT07286253Phase 2
• AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT StudyRecruitingNCT07285395Phase 1
• SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARCRecruitingNCT07284992Phase 2
• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerRecruitingNCT07284849Phase 3
• Amping up With PemJAKRecruitingNCT07283822Phase 2
• Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingNCT07283731Phase 2
• Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)RecruitingNCT07283692Phase 2
• Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingNCT07282509Phase 1/2
• A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerRecruitingNCT07281976Phase 1/2
• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisRecruitingNCT07281924Phase 1/2
• Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingNCT07281768Phase 2
• Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRCRecruitingNCT07281716Phase 1/2
• Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07281664Not applicable
• Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaRecruitingNCT07281417Phase 2
• A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung CancerNot yet recruitingNCT07281209Phase 2
• Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsRecruitingNCT07280832Phase 1/2
• A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder CancerNot yet recruitingNCT07279597Phase 2
• PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal CancerNot yet recruitingNCT07277842Phase 3
• Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesRecruitingNCT07277322Phase 1/2
• Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabRecruitingNCT07276100Phase 2

← Immune Checkpoint Inhibitors overview